These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21619856)

  • 81. Meeting Report: 2013 PDA Virus & TSE Safety Forum.
    Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Hubbard BR; Kreil TR; Ruffing M; Ruiz S; Scott D; Silvester G
    PDA J Pharm Sci Technol; 2014; 68(3):193-214. PubMed ID: 25188343
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice--validation of virus removal and inactivation.
    Trijzelaar B
    Biotherapy; 1993; 6(2):93-102. PubMed ID: 8398576
    [TBL] [Abstract][Full Text] [Related]  

  • 83. European Pharmacopoeia's Approach to Cell and Gene Therapy: Focus on How Gene Therapy Texts Are Evolving.
    Kolaj-Robin O; Duffour MT
    Adv Exp Med Biol; 2023; 1430():59-70. PubMed ID: 37526842
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Made in China.
    Haller C
    J Med Toxicol; 2008 Jun; 4(2):141-2. PubMed ID: 18570176
    [No Abstract]   [Full Text] [Related]  

  • 85. Massively parallel sequencing: a new tool in virus discovery and vaccine safety.
    Onions D
    Bull Mem Acad R Med Belg; 2011; 166(10-12):404-6. PubMed ID: 23082505
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The application of gene amplification technology to plasma-derived products: a view from a European member state.
    Silverster G
    Biologicals; 1998 Jun; 26(2):131-2. PubMed ID: 9811519
    [No Abstract]   [Full Text] [Related]  

  • 87. Virus & TSE safety forum 2008.
    Robertson JS; Blümel J; Brorson K; Gröner A; Kreil TR; Ruiz S; Willkommen H
    Biologicals; 2009 Oct; 37(5):345-54. PubMed ID: 19646899
    [No Abstract]   [Full Text] [Related]  

  • 88. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
    Dwenger A; Strassburger J; Schwerdtfeger W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Current issues in the regulation of human tissue-engineering products in the European Union.
    Heinonen M; Oila O; Nordström K
    Tissue Eng; 2005; 11(11-12):1905-11. PubMed ID: 16411837
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Bovine serum--regulatory issues.
    Robertson JS
    Dev Biol (Basel); 2006; 123():269-72; discussion 291-308. PubMed ID: 16566452
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The in vitro evidence for an effect of high homeopathic potencies--a systematic review of the literature.
    Witt CM; Bluth M; Albrecht H; Weisshuhn TE; Baumgartner S; Willich SN
    Complement Ther Med; 2007 Jun; 15(2):128-38. PubMed ID: 17544864
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Manufacturing of Plasma-Derived Medicinal Products: Qualification Process of Plasma Suppliers.
    Parés C; Martínez M; Messeguer J; Rodríguez E
    PDA J Pharm Sci Technol; 2015; 69(5):620-30. PubMed ID: 26429109
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Anthroposophic treatment in pediatrics--a critical analysis].
    Burkhard B
    Versicherungsmedizin; 2004 Dec; 56(4):197-9. PubMed ID: 15633774
    [No Abstract]   [Full Text] [Related]  

  • 94. Chinese plasma-derived products supply under the lot release management system in 2007-2011.
    Zhang X; Ye S; Du X; Yuan J; Zhao C; Li C
    Biologicals; 2013 Nov; 41(6):364-7. PubMed ID: 23856276
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Assessing and regulating homeopathic products.
    Fears R; Griffin G; Larhammar D; Ter Meulen V; van der Meer JWM
    J Intern Med; 2017 Dec; 282(6):563-565. PubMed ID: 28944510
    [No Abstract]   [Full Text] [Related]  

  • 96. Microbial limits reviewed: the basis for unique Australian regulatory requirements for microbial quality of non-sterile pharmaceuticals.
    Tang S
    PDA J Pharm Sci Technol; 1998; 52(3):100-9. PubMed ID: 9691672
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Current concept for the microbiological safety of cell-based medicinal products].
    Schurig U; Karo JO; Sicker U; Spindler-Raffel E; Häckel L; Spreitzer I; Bekeredjian-Ding I
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1225-32. PubMed ID: 26369764
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Study on differentiation and extract determination of Porcellio scaber and Armadillidium vulgare].
    Zhao JF; Wang YH; Yang L; Niu YG
    Zhong Yao Cai; 2012 Aug; 35(8):1205-7. PubMed ID: 23320347
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Virus safety of intravenous immunoglobulin: future challenges.
    Boschetti N; Stucki M; Späth PJ; Kempf C
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):333-44. PubMed ID: 16391410
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Historical data analyses and scientific knowledge suggest complete removal of the abnormal toxicity test as a quality control test.
    Garbe JHO; Ausborn S; Beggs C; Bopst M; Joos A; Kitashova AA; Kovbasenco O; Schiller CD; Schwinger M; Semenova N; Smirnova L; Stodart F; Visalli T; Vromans L
    J Pharm Sci; 2014 Nov; 103(11):3349-3355. PubMed ID: 25209378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.